Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii

Motaouakkil, S.; Чарра, Б.; Hachimi, Abdelhamid; Nejmi, H.; Benslama, A.; Elmdaghri, Naima; Belabbes, H.; Benbachir, M.

doi:10.1016/j.jinf.2005.11.019

Cited by 152 publications

(114 citation statements)

References 28 publications

(26 reference statements)

Supporting

Mentioning

111

Contrasting

Unclassified

Order By: Relevance

“…The first was an observational study evaluating rifampin (10 mg/kg b.i.d. )-colistin combination therapy for 26 patients (176). The cases treated with combination therapy had a mixture of bacteremia and pneumonia but had a low severity of illness (APACHE II score of 6).…”

Section: Other Diseasesmentioning

confidence: 99%

See 1 more Smart Citation

Rifampin Combination Therapy for Nonmycobacterial Infections

2010

View full text Add to dashboard Cite

SUMMARY The increasing emergence of antimicrobial-resistant organisms, especially methicillin-resistant Staphylococcus aureus (MRSA), has resulted in the increased use of rifampin combination therapy. The data supporting rifampin combination therapy in nonmycobacterial infections are limited by a lack of significantly controlled clinical studies. Therefore, its current use is based upon in vitro or in vivo data or retrospective case series, all with major limitations. A prominent observation from this review is that rifampin combination therapy appears to have improved treatment outcomes in cases in which there is a low organism burden, such as biofilm infections, but is less effective when effective surgery to obtain source control is not performed. The clinical data support rifampin combination therapy for the treatment of prosthetic joint infections due to methicillin-sensitive S. aureus (MSSA) after extensive debridement and for the treatment of prosthetic heart valve infections due to coagulase-negative staphylococci. Importantly, rifampin-vancomycin combination therapy has not shown any benefit over vancomycin monotherapy against MRSA infections either clinically or experimentally. Rifampin combination therapy with daptomycin, fusidic acid, and linezolid needs further exploration for these severe MRSA infections. Lastly, an assessment of the risk-benefits is needed before the addition of rifampin to other antimicrobials is considered to avoid drug interactions or other drug toxicities.

show abstract

Section: Other Diseasesmentioning

confidence: 99%

“…Those authors reported 6 deaths but no hepatotoxicity, nephrotoxicity, or rifampin resistance (22). Both of these studies were limited by the absence of a control group for comparison of colistin monotherapy (22,176).…”

Section: Other Diseasesmentioning

confidence: 99%

Rifampin Combination Therapy for Nonmycobacterial Infections

2010

View full text Add to dashboard Cite

show abstract

“…Polymyxin B was administered by inhalation. Actually, Michalopoulos and Motaouakkil (1,3,7) concluded that aerosolized colistin should be a beneficent adjunctive therapy in the management of nosocomial pneumonia due to multi-resistant Gram-negative bacteria. In our series, none of the patients experienced chest tightness, bronchoconstriction, or apnea.…”

Section: Discussionmentioning

confidence: 99%

Aerosolized colistin in the treatment of multiresistant Pseudomonas aeruginosa nosocomial pneumonia

Чарра¹,

Hachimi²,

Benslama³

et al. 2009

View full text Add to dashboard Cite

Introduction. Multiresistant Pseudomonas aeruginosa (MRPA) nosocomial pneumonia is a significant cause of mortality and (2006)(2007) days. The bronchial sampling technique used was broncho-alveolar lavage. The mean delay of infection (duration between intubation and pneumonia diagnosis) was 7 ± 2 days. Isolated MRPA was susceptible only to colistin. The treatment was aerosolized colistin for all patients (4 MUI/day). A positive blood culture (n=5) was a prerequisite for administering colistin intravenously (4 MUI/day

show abstract

“…By altering membrane permeability, colistin may facilitate rifampicin entry within the bacterial cell and therefore enhance its killing activity (67,68). Three uncontrolled clinical studies have assessed the safety and clinical efficacy of the colistin-rifampicin combination, showing very high overall response rates (69)(70)(71).…”

Section: Colistin-rifampicinmentioning

confidence: 99%

Intravenous polymyxins: Revival with puzzle

Fei

et al. 2017

BST

View full text Add to dashboard Cite

Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii

Cited by 152 publications

References 28 publications

Rifampin Combination Therapy for Nonmycobacterial Infections

Rifampin Combination Therapy for Nonmycobacterial Infections

Aerosolized colistin in the treatment of multiresistant Pseudomonas aeruginosa nosocomial pneumonia

Intravenous polymyxins: Revival with puzzle

Contact Info

Product

Resources

About